Stephens Consulting’s Royalty Pharma RPRX Stock Holding History

Stephens Consulting’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20	Closed	-$721	–	1007
2025 Q2	$721	Buy	+20	New	+$663	﹤0.01%	786

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's RPRX Position: Q3 2025 in Review

Stephens Consulting sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 20 shares — an estimated $721 sold.

Stephens Consulting first reported a position in RPRX in Q2 2025 and held it in 1 quarter. The position peaked at $721 in Q2 2025. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

Stephens Consulting reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
Stephens Consulting sold 20 Royalty Pharma shares in Q3 2025, an estimated $721.
Stephens Consulting first reported a position in Royalty Pharma in Q2 2025 and held it in 1 quarter.
Stephens Consulting's Royalty Pharma position peaked at $721 in Q2 2025.
487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.